NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids Status
Recruiting
N/A
Interventional Study
Obese Adults
MDD
At a Glance
- Age
- 18 – 54
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 50 (estimated)
- Sponsor
- National Science and Technology Council, Taiwan · Government
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
A 12-week, randomized, placebo-controlled trial testing the efficacy of n-3 PUFA treatment (EPA, 2 g/day) in alleviating depressive symptoms in a subgroup of obese subjects with comorbid depression and low n-3 PUFA status (n-3 index \< 8%) (81), from the Taiwanese cohort. Associations with PLA2/COX2 genotypes, lifestyle, nutritional profiles and gut microbiota will also be determined.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Major depressive disorder.
* Antidepressant drug-free.
Exclusion Criteria:
* Schizophrenia
* Mania
* Anxiety disorders (except for social phobia and generalized anxiety that are often comorbid with MDD)
* Obsessive-compulsive disorder
* Post-traumatic stress disorder
* Alcoh…
Contacts
No contact information available.